Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Castle Biosciences CEO Derek Maetzold executed multiple sales of common stock on April 8th and 9th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Derek Maetzold, the President and CEO of Castle Biosciences, sold shares of common stock on April 8th and 9th, 2025.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2024.
• On April 8th, shares were sold at a weighted average price of $20.03.
• On April 9th, shares were sold at a weighted average price of $20.219.
• The transactions involved both direct holdings and indirect holdings through various trusts.
• Following the reported transactions, Maetzold continues to hold a significant number of shares both directly and indirectly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Risks

• Sales by a company's CEO, even under a pre-arranged plan, can sometimes be perceived negatively by the market.

Industry Context

Insider sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on material non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if the market interprets them negatively, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Form 4, insider trading, Rule 10b5-1, stock sale, Derek Maetzold, Castle Biosciences, CSTL